A18830 Cardioprotective role of hesperidin in experimentally induced cardiac hypertrophy in rats

Abstract

Objectives: Cardiac hypertrophy is a leading cause for heart failure which in turn has a high mortality rate. Hesperidin (HES) is a flavanone glycoside with agonistic activity on Peroxisome Proliferator-Activated Receptor gamma (PPAR-γ), an inhibitor of cardiac hypertrophy signaling pathways. Therefore, we investigated the cardio-protective effect of hesperidin in isoproterenol induced cardiac hypertrophy. Methods: Male albino Wistar rats were divided into 6 groups (n = 6) and administered isoproterenol (3 mg/kg/day s.c.) or hesperidin (200 mg/kg/day, p.o.) and isoprotereol or enalapril (30 mg/kg/day p.o.) and isoprotereol or a combination of hesperidin and enalapril for 28 days. On the 29th day, rats were anaesthetized followed by cannulation of right coronary artery to record hemodynamic parameters. Blood sample was collected and heart was excised to evaluate for biochemical, histopathological, ultrastructural and immuohistochemical studies. Results: Hesperidin significantly normalized heart weight/body weight ratio and cardiomyocyte area, improved cardiac function and attenuated pathological changes. A decline in the levels of cardiac injury markers (CK-MB, LDH) and inflammatory markers TNF-α, IL-6) was observed. Additionally hesperidin suppressed oxidative stress and apoptosis along with an increased PPAR-γ expression. Conclusion: Hesperidin is a promising molecule for attenuation of cardiac hypertrophy and acts by the virtue of its PPAR-γ agonistic anti-inflammatory, anti-apoptotic and antioxidant properties